Male Hypogonadism Market
Number of pages: 100 | Report Format: PDF | Published date: April 14, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.51 billion |
|
Market Size Value in 2031 |
US$ 5.44 billion |
|
CAGR |
5.0% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Drug Delivery, Therapy, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global male hypogonadism market was valued at US$ 3.51 billion in 2022 and is expected to register a revenue CAGR of 5.0% to reach US$ 5.44 billion by 2031.
Male Hypogonadism Market Fundamentals
Male hypogonadism is a medical condition characterized by a deficiency in testosterone production or other reproductive hormones. Testosterone is the primary male sex hormone responsible for developing male sex characteristics such as facial hair, deepening of the voice, and muscle development. Hypogonadism can be either primary or secondary. Primary hypogonadism occurs when the testes are unable to produce testosterone due to a problem within the testes themselves. Some examples of primary hypogonadism include Klinefelter syndrome, undescended testicles, and mumps orchitis. While secondary hypogonadism occurs when there is a problem with the hypothalamus or pituitary gland, which regulates testosterone production, secondary hypogonadism includes conditions such as Kallmann syndrome, pituitary disorders, and inflammatory disease.
The symptoms of male hypogonadism symptoms include reduced muscle mass and strength, decreased bone density, erectile dysfunction, infertility, decreased libido, fatigue, and depression. Hypogonadism diagnosis can be through a combination of physical examination, blood tests, and hormone level evaluations. Male hypogonadism medication/treatment includes testosterone replacement therapy (TRT), which involves administering testosterone through injections, gels, patches, or pellets.
[97686]
Male Hypogonadism Market Dynamics
The rising prevalence of male hypogonadism globally significantly increases the demand for male hypogonadism treatment. Male hypogonadism is more prevalent as compared to female hypogonadism. The aging population is a significant driver of the male hypogonadism market, as the condition’s prevalence is expected to increase. According to the Endocrine Society, approximately 35% of men older than 45 years of age and 30-50% of men with obesity or type 2 diabetes have hypogonadism. There is a growing awareness among healthcare providers and patients about hypogonadism, which is driving demand for diagnosis and treatment. Many patients who experience symptoms associated with hypogonadism, such as low libido and fatigue, may not realize they have the condition. Increased awareness can lead to more patients seeking diagnosis and treatment.
Moreover, changes in lifestyle, including increasing sedentary lifestyles and poor dietary habits, contribute to an increase in the prevalence of hypogonadism. For example, obesity is a risk factor for hypogonadism, as excess body fat can lead to decreased testosterone production. Regulatory approvals for new therapies and treatment options contribute to the market’s revenue growth by increasing patient options. Incorporating advanced technology, such as new delivery methods for testosterone replacement therapy, makes it easier for patients to receive treatment, driving the male hypogonadism market revenue growth. Patients with hypogonadism may require ongoing treatment, and the costs associated with diagnosis and treatment can be significant. Increased healthcare expenditure, particularly in developed countries, contributes to the revenue growth of male hypogonadism.
However, the use of testosterone replacement therapy (TRT) has been associated with an increased risk of cardiovascular events such as heart attack and stroke, as well as prostate cancer which is restricting the male hypogonadism market revenue growth. Societal stigma related to male hypogonadism is also cramping the overall market growth as men may feel embarrassed by the condition, which may prevent them from seeking treatment.
Male Hypogonadism Market Ecosystem
The global male hypogonadism market is analyzed from four perspectives: type, drug delivery, therapy, and region.
Male Hypogonadism Market by Type
[96766]
Based on the type, the global male hypogonadism market is segmented into Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others.
The pituitary disorders segment dominated the male hypogonadism market with the largest revenue share. Pituitary disorders are one of the common causes of hypogonadism; this high pituitary disorders prevalence drives demand for diagnosis and treatment, contributing to the dominance of the pituitary disorders segment. Pituitary disorders are relatively easy to diagnose using blood tests to measure levels of LH and FSH. This ease of diagnosis makes it easier for healthcare providers to identify patients with hypogonadism due to pituitary disorders, contributing to the dominance of the pituitary disorders segment. TRT is an effective treatment for hypogonadism due to pituitary disorders, as it can replace the testosterone that the body is no longer producing. Other treatments, such as human chorionic gonadotropin (hCG) or clomiphene citrate, may be used to stimulate testosterone production. The availability of effective treatment options influences the dominance of the pituitary disorders segment. Pituitary disorders and their relationship to hypogonadism have been the focus of significant research over the years, leading to a better understanding of the condition and improved treatment options.
The Klinefelter syndrome segment expects lucrative revenue growth during the forecast period. The increasing incidence of Klinefelter syndrome is boosting segmental growth. According to the National Organization for Rare Disorders in the U.S., approximately 1 in 500-1,000 males are affected by Klinefelter syndrome. It is estimated that 3,000 affected boys are born each year. There is increasing awareness of Klinefelter syndrome among healthcare providers and patients, leading to earlier diagnosis and treatment. This greater awareness drives demand for diagnosis and treatment options, contributing to segmental revenue growth. Currently, limited treatment options are available for Klinefelter syndrome, and TRT is often the primary treatment used. However, TRT may not be sufficient for all patients, and there is a need for additional treatment options. This unmet medical need is driving research and development of new treatment options. Advances in genetic testing and diagnosis have made it easier to identify patients with Klinefelter syndrome. This improved diagnosis is driving demand for treatment options and contributing to the rapid revenue of this segment.
Male Hypogonadism Market by Drug Delivery
Based on the drug delivery, the global male hypogonadism market is segmented into oral, topical, and injectables.
The topical segment accounted for a significant male hypogonadism market share in 2022. Topical therapy is a convenient and non-invasive treatment option for hypogonadism. Patients can apply the medication at home, which may be more convenient than injections. This convenience contributes to the dominance of the topical segment. Topical medications are widely available and may be prescribed by healthcare providers to treat hypogonadism. This wide availability contributes to the dominance of the topical segment. Topical medications are generally considered effective for treating hypogonadism, and they can provide consistent testosterone levels over time. This efficacy contributes to the topical segment’s revenue growth. Topical medications are associated with fewer side effects than other medication forms, such as injections. This may make them a more desirable treatment option for some patients, boosting segmental revenue growth.
The oral segment accounted for a prominent revenue share of the male hypogonadism market. Some patients may prefer oral medications over other forms of drug delivery, such as injections. This preference may be due to convenience, ease of use, or personal preference. Oral medications are widely available and may be prescribed by healthcare providers to treat hypogonadism. Oral medications are generally considered effective for treating hypogonadism, and they can provide consistent testosterone levels over time. Oral medications have been on the market for many years and have an established presence in treating hypogonadism. This established market presence contributes to the market revenue share of the oral segment. Some healthcare providers may prefer to prescribe oral medications over other forms for certain patients, fueling segmental revenue growth.
Male Hypogonadism Market by Therapy
Based on the therapy, the global male hypogonadism market is segmented into testosterone replacement therapy, gonadotropin, and gonadotropin-releasing hormone therapy.
With the highest revenue share testosterone replacement therapy segment dominated the male hypogonadism market. Testosterone deficiency is a common cause of male hypogonadism, and TRT is the primary treatment for this condition. The high prevalence of testosterone deficiency is boosting segmental revenue growth. TRT is generally considered effective for treating hypogonadism, and it can provide consistent testosterone levels over time. TRT medications are widely available and may be prescribed by healthcare providers to treat hypogonadism. Many healthcare providers may prefer to prescribe TRT over other forms of treatment for hypogonadism.
Male Hypogonadism Market by Region
Geographically, the global male hypogonadism market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America region has the largest male hypogonadism market revenue in terms of revenue generation. North America has a high prevalence of hypogonadism, which drives the demand for treatments such as testosterone replacement therapy (TRT) and other hormone therapies. There is an increasing awareness of male hypogonadism in North America, leading to more men seeking diagnosis and treatment. This increased awareness also leads to more healthcare providers becoming knowledgeable about the condition and prescribing appropriate treatments. North America has an advanced healthcare infrastructure, including many specialty clinics, hospitals, and healthcare providers. This infrastructure enables the diagnosis and treatment of hypogonadism promptly and effectively. The aging male population in North America is increasing, which is a major risk factor for developing hypogonadism. This demographic shift is driving the demand for hypogonadism treatments in the region. The healthcare policies in North America are favorable toward the diagnosis and treatment of hypogonadism. This includes coverage for hormone therapy by insurance companies and government healthcare programs, which makes treatment more accessible and affordable for patients.
Male Hypogonadism Competitive Landscape
The prominent players operating in the global male hypogonadism market are:
Male Hypogonadism Strategic Developments
The expected size of the global male hypogonadism market in 2031 is US$ 5.44 billion.
Male hypogonadism is a medical condition characterized by a deficiency in the production of testosterone or other reproductive hormones. Testosterone is the primary male sex hormone responsible for the development of male sex characteristics such as facial hair, deepening of the voice, and muscle development.
North America has the largest market share in terms of revenue. Asia Pacific is expected to account for the fastest revenue growth.
The prominent players operating in the global male hypogonadism market are Endo International Plc., AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG.
During the forecast period, the revenue CAGR of the global male hypogonadism market is expected to be 5.0%.
*Insights on financial performance are subject to the availability of information in the public domain